Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 1999

View Archived Issues

Amrad: Annual Report 1998

Corixa is first to achieve clinical testing of a microsphere-encapsulated peptide cancer vaccine

Experiments show skeletal muscle capable of bone formation when transplanted into animals

CytRx reaches midpoint in Flocor trial

Orphan Medical begins Treatment IND trial of Xyrem in narcolepsy

Axcan and Labopharm to develop controlled-release trimebutine formulation

Connetics begins pivotal trial of relaxin for scleroderma therapy

New compounds from Pharmacia & Upjohn interfere in the kynurenine metabolic pathway

New Lilly SERMs especially useful for breast cancer

Ilex Oncology initiates phase III trial of DFMO

ICE/ced-3 cysteine protease inhibitors in development at Idun

FDA grants priority review status to U.S. Bioscience's sNDA for Ethyol

Tachykinin antagonists specifically claimed for asthma by Merck

NNRTIs from Boehringer Ingelheim effective against mutant viruses

Status updated for Esteve's atypical antipsychotic E-5842

Taiwan university researchers present new ATP-sensitive potassium channel opener

AutoImmune and Teva to collaborate on oral immune therapies

Advisory committee votes not to recommend approval of Relenza

Aurora enters assay development and screening agreement with P&U

Strategic review of Novopharm Biotech's R&D program leads to discontinuation of GPI-2A

New tradename announced for Magainin's pexiganan

Celtrix adds another patent to its SomatoKine portfolio

AC-178335: new pure somatostatin antagonist that induces GH release in vivo

Orally active TxA2 antagonist in clinical development at Zeria

MS&D launches alopecia treatment in Spain

Healing of severe esophagitis linked to improvement in peristaltic dysfunction

Preclinical study confirms antiinflammatory activity of raxofelast

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...